San Francisco, California, November 06, 2018: According to a recent market research report by TMR Research, The global market for portal hypertension is likely to witness a promising upward trajectory over the period between 2017 and 2025, driven chiefly to the rising global prevalence of liver cirrhosis, which is one of the leading causes of portal hypertension and other hepatic diseases. The report is titled “Portal Hypertension Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025.”
Get Sample Copy of this Report @
The market presently has a limited set of treatment options owing to the dearth of specialized drugs for the treatment of the condition. The market is currently being ruled by generic drugs, including somatostatin and its analogues, beta blockers, and vasopressin and its analogues. This hints at the lucrative growth opportunities that companies have in the field with effective R&D activities.
The market has seen a vast rise in drugs entering the clinical trial phases and is reaching a point of evolution. Noteworthy candidates that are presently in the phase III clinical trial are Sapropterin, Udenafil, and Octreolin. When these drugs are launched and approved, they will have the chance of acquiring a substantial share in the global portal hypertension market in the next few years.
Read Comprehensive Overview of Report @
Based on diagnosis, Duplex Doppler ultrasonography has remained one of the most promising candidate in the market owing to its high rate of efficiency in diagnosing portal hypertension. Besides, technologies such as computed tomography, angioplasty, scanning, magnetic resonance imaging, and bleeding scan are also used for the diagnosis of the condition.
Some of the leading companies operating in the global portal hypertension market are Dong-A Socio Holdings Co Ltd., Ono Pharmaceutical Co., Ltd., Genextra S.p.a., Debiovision, Inc., Novartis AG, Aptalis Pharma Inc., United Therapeutics Corporation, Govind Ballabh Pant Hospital, Gilead Sciences, Inc., Dr. Falk Pharma GmbH, and Chiasma, Inc.